
After an extended assessment period, the FDA has ruled on Incyte's topical formulation of eczema treatment ruxolitnib.
The authority has approved the treatment for use in atopic dermatitus (commonly known as eczema). The cream will be marketed under the name of Opzelura, while the first version, which is administered in tablet form, is called Jakavi or Jakafi, depending on the market.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app